2 results match your criteria: "BMT Clinical Pharmacist[Affiliation]"
Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m versus 140 mg/m.
Clin Lymphoma Myeloma Leuk
September 2024
Clinical Professor, University of Georgia College of Pharmacy, BMT Clinical Pharmacist, Wellstar-MCG Health. Electronic address:
Article Synopsis
- - The study aimed to compare the efficacy and safety of two doses of melphalan (standard dose 200 mg/m² vs. reduced dose 140 mg/m²) for patients with multiple myeloma undergoing autologous stem cell transplantation, due to the lack of standard criteria for dose reduction.
- - A total of 322 patients were reviewed, showing no significant differences in progression-free survival (PFS) and overall survival (OS) between the two dosing groups, regardless of age or kidney function.
- - The findings suggest that reducing the dose of melphalan does not impact safety or efficacy, indicating the need for larger randomized trials to further investigate these results.
Chemotherapy-induced nausea and vomiting: optimizing prevention and management.
Am Health Drug Benefits
July 2012
Hematology/oncology clinical pharmacist practitioner, University of North Carolina Hospitals and Clinics, Chapel Hill, NC.
Background: Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patients' quality of life and on their ability to tolerate and comply with therapy. Despite advances in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), these side effects remain among the most distressing for patients.
Objective: To discuss CINV and the current pharmacologic approaches to its management.